Azitra, Inc. (AZTR)Healthcare | Biotechnology | Branford, United States | NYSE American
0.21 USD
0.00
(-1.349%) ⇩
(April 20, 2026, 4 p.m.
EDT)
Short-term: ★★☆☆☆ | Long-term: ☆☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 18, 2026, 10:34 p.m. EDT
AZTR presents a clear sell/short opportunity for the short term due to severe negative momentum (-20% predicted adjustment) and extreme price volatility post-news catalyst. Long-term ownership is a value trap characterized by deteriorating fundamentals (negative EPS, negative free cash flow) and catastrophic stock dilution (reverse split + private placements), rendering the recent price surges irrelevant to intrinsic value. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.250029 |
| MSTL | 0.291046 |
| AutoETS | 0.314693 |
| AutoARIMA | 0.319824 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 80% |
| H-stat | 0.08 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.458 |
| Excess Kurtosis | -0.91 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 11.104 |
| Market Cap | 3,432,796 |
| Forward P/E | -0.41 |
| Beta | -2.18 |
| Previous Name | Azitra Inc |
| Website | https://azitrainc.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.88802814 |
| Address1 | 21 Business Park Drive |
| All Time High | 1,036.0 |
| All Time Low | 0.1 |
| Ask | 0.2128 |
| Ask Size | 800 |
| Average Daily Volume10 Day | 634,040 |
| Average Daily Volume3 Month | 12,532,585 |
| Average Volume | 12,532,585 |
| Average Volume10Days | 634,040 |
| Beta | -2.175 |
| Bid | 0.2142 |
| Bid Size | 300 |
| Book Value | 0.354 |
| City | Branford |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.212 |
| Current Ratio | 2.827 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 0.2172 |
| Day Low | 0.2082 |
| Debt To Equity | 11.104 |
| Display Name | Azitra |
| Ebitda | -10,828,596 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.165 |
| Enterprise Value | 1,786,790 |
| Eps Forward | -0.52 |
| Eps Trailing Twelve Months | -2.25 |
| Esg Populated | 0 |
| Exchange | ASE |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 0.20508 |
| Fifty Day Average Change | 0.006919995 |
| Fifty Day Average Change Percent | 0.033742905 |
| Fifty Two Week Change Percent | -88.80281 |
| Fifty Two Week High | 2.666667 |
| Fifty Two Week High Change | -2.454667 |
| Fifty Two Week High Change Percent | -0.92050004 |
| Fifty Two Week Low | 0.1 |
| Fifty Two Week Low Change | 0.111999996 |
| Fifty Two Week Low Change Percent | 1.1199999 |
| Fifty Two Week Range | 0.1 - 2.666667 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,686,922,200,000 |
| Float Shares | 16,181,751 |
| Forward Eps | -0.52 |
| Forward P E | -0.4076923 |
| Free Cashflow | -6,947,441 |
| Full Exchange Name | NYSE American |
| Full Time Employees | 13 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.03384 |
| Held Percent Institutions | 0.01392 |
| Implied Shares Outstanding | 16,192,438 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,755,734,400 |
| Last Split Factor | 15:100 |
| Long Business Summary | Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and topical live biotherapeutic products to treat skin diseases in the United States. The company develops ATR-04, a genetically modified strain of S. epidermidis that is in a Phase 1/2 clinical trial for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor targeted therapy; ATR-12, a genetically modified strain of S. epidermidis, which is in a Phase 1b/2a clinical trial for treating Netherton syndrome, a skin disease; and ATR-01, a genetically modified strain of S. epidermidis that expresses an engineered recombinant human filaggrin protein, which is in the IND-enabling phase for treating ichthyosis vulgaris, a skin disease. It has a joint development agreement with Bayer for the identification and characterization of S. epidermidis strains for topical formulations. Azitra, Inc. was incorporated in 2014 and is headquartered in Branford, Connecticut. |
| Long Name | Azitra, Inc. |
| Market | us_market |
| Market Cap | 3,432,796 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_404021170 |
| Most Recent Quarter | 1,767,139,200 |
| Name Change Date | 2,026-04-20 |
| Net Income To Common | -10,955,370 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 3,432,796 |
| Number Of Analyst Opinions | 2 |
| Open | 0.21 |
| Operating Cashflow | -11,224,125 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 203 646 6446 |
| Pre Market Change | 0.0031999946 |
| Pre Market Change Percent | 1.5209099 |
| Pre Market Price | 0.2136 |
| Pre Market Time | 1,776,775,603 |
| Prev Name | Azitra Inc |
| Previous Close | 0.2149 |
| Price Hint | 4 |
| Price To Book | 0.59887004 |
| Profit Margins | 0.0 |
| Quick Ratio | 2.069 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.0029 |
| Regular Market Change Percent | -1.34947 |
| Regular Market Day High | 0.2172 |
| Regular Market Day Low | 0.2082 |
| Regular Market Day Range | 0.2082 - 0.2172 |
| Regular Market Open | 0.21 |
| Regular Market Previous Close | 0.2149 |
| Regular Market Price | 0.212 |
| Regular Market Time | 1,776,715,200 |
| Regular Market Volume | 406,910 |
| Return On Assets | -1.10692 |
| Return On Equity | -2.30651 |
| Sand P52 Week Change | 0.34445214 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 16,192,438 |
| Shares Percent Shares Out | 0.1503 |
| Shares Short | 2,434,370 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 123,961 |
| Short Name | Azitra Inc |
| Short Percent Of Float | 0.1504 |
| Short Ratio | 0.08 |
| Source Interval | 15 |
| State | CT |
| Symbol | AZTR |
| Target High Price | 1.7 |
| Target Low Price | 1.0 |
| Target Mean Price | 1.35 |
| Target Median Price | 1.35 |
| Total Cash | 2,068,083 |
| Total Cash Per Share | 0.128 |
| Total Debt | 422,077 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.25 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 0.57122 |
| Two Hundred Day Average Change | -0.35921997 |
| Two Hundred Day Average Change Percent | -0.6288645 |
| Type Disp | Equity |
| Volume | 406,910 |
| Website | https://azitrainc.com |
| Zip | 6,405 |